12.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.20
Aprire:
$12.28
Volume 24 ore:
240.39K
Relative Volume:
0.58
Capitalizzazione di mercato:
$326.25M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-10.37
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
-5.12%
1M Prestazione:
-6.66%
6M Prestazione:
-31.18%
1 anno Prestazione:
-60.37%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARCT
Arcturus Therapeutics Holdings Inc
|
12.03 | 325.18M | 157.75M | -29.73M | -21.00M | -1.16 |
![]()
ONC
Beigene Ltd Adr
|
238.19 | 25.23B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.67 | 113.16B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 40.65M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.09 | 64.41B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.58 | 6.18B | 0 | -153.72M | -103.81M | -2.00 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-28 | Iniziato | BTIG Research | Buy |
2024-08-12 | Iniziato | Leerink Partners | Outperform |
2023-12-13 | Iniziato | Canaccord Genuity | Buy |
2023-07-24 | Iniziato | William Blair | Outperform |
2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2022-11-14 | Ripresa | Wells Fargo | Overweight |
2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
2021-08-11 | Downgrade | Goldman | Neutral → Sell |
2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
2021-06-25 | Ripresa | Goldman | Neutral |
2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
2021-01-07 | Iniziato | Wells Fargo | Overweight |
2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
2020-12-08 | Reiterato | B. Riley Securities | Buy |
2020-12-07 | Reiterato | B. Riley Securities | Buy |
2020-10-26 | Iniziato | Barclays | Overweight |
2020-10-06 | Iniziato | Citigroup | Buy |
2020-08-26 | Iniziato | Piper Sandler | Overweight |
2020-07-30 | Ripresa | ROTH Capital | Buy |
2020-07-16 | Iniziato | Raymond James | Outperform |
2020-07-13 | Iniziato | B. Riley FBR | Buy |
2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
2020-02-11 | Iniziato | Robert W. Baird | Outperform |
2020-02-07 | Iniziato | Guggenheim | Buy |
2020-02-06 | Iniziato | Guggenheim | Buy |
2019-04-05 | Iniziato | H.C. Wainwright | Buy |
2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcturus Therapeutics (ARCT) Surpasses Q1 Revenue Expectations | - GuruFocus
ARCTURUS THERAPEUTICS Earnings Results: $ARCT Reports Quarterly Earnings - Nasdaq
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com Canada
Arcturus Therapeutics stock jumps 7% despite Q1 loss - Investing.com Australia
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress - Business Wire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Dimensional Fund Advisors LP - Defense World
Arcturus Therapeutics (ARCT) to Release Quarterly Earnings on Monday - Defense World
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance
MetLife Investment Management LLC Has $283,000 Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Barclays PLC Sells 7,333 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Yahoo Finance
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $59.20 - Defense World
Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Ther - GuruFocus
Legal & General Group Plc Has $410,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
LPL Financial LLC Has $195,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wells Fargo & Company MN Acquires 7,785 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):